MARKET

NEO

NEO

Neogenomics Inc
NASDAQ
9.25
+0.54
+6.20%
Closed 19:21 10/04 EDT
OPEN
8.98
PREV CLOSE
8.71
HIGH
9.43
LOW
8.94
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
47.67
52 WEEK LOW
6.85
MARKET CAP
1.16B
P/E (TTM)
-7.7672
1D
5D
1M
3M
1Y
5Y
After sharp right turn, U.S. Supreme Court conservatives step on the gas
After sharp right turn, U.S. Supreme Court conservatives step on the gas
Reuters · 09/28 10:00
NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022
NeoGenomics, Inc. (NASDAQ:NEO),a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announces that its liquid biopsy focused subsidiary Inivata Limited ("Inivata"), alongside collaborators, wil...
ACCESSWIRE · 09/07 06:00
Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2022
Upgrades
Benzinga · 08/26 14:55
Benchmark Downgrades NeoGenomics to Hold
Benchmark analyst Bruce Jackson downgrades NeoGenomics (NASDAQ:NEO) from Buy to Hold.
Benzinga · 08/26 11:43
Benchmark Downgrades NeoGenomics to Hold From Buy
Benchmark Downgrades NeoGenomics to Hold From Buy
MT Newswires · 08/26 08:44
Turnaround For This Cancer Genetics Testing Firm Could Take Years, Analyst Says While Downgrading Stock
Benzinga · 08/22 19:29
NeoGenomics cut to Hold at Needham citing longer turnaround
Needham downgraded NeoGenomics, Inc. (NASDAQ:NEO), an operator of canc...
Seekingalpha · 08/22 18:49
NeoGenomics Stock Is Downgraded. A ‘Turnaround Appears Daunting.’
A Wall Street bull finally threw in the towel on NeoGenomics stock. Needham’s Mike Matson, who rated the stock at Buy for more than a year and a half, flipped his rating to Hold, saying the shares are fairly valued and that he believes the pharma compan...
Barrons.com · 08/22 15:51
More
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. It offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. It operates testing laboratories in United States, Europe and Asia.

Webull offers kinds of NeoGenomics, Inc. stock information, including NASDAQ:NEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NEO stock methods without spending real money on the virtual paper trading platform.